Karyopharm Therapeutics Inc.'s submission of Phase III data near the end of the review cycle for the company's multiple myeloma treatment Xpovio (selinexor) helped to save the drug from a complete response letter and ultimately score an accelerated approval following a three-month user fee date extension, a US Food and Drug Administration review document shows.
The FDA granted Xpovio, a nuclear export inhibitor, accelerated approval on 3 July 2019 in combination with dexamethasone for the...








